Atosiban as a tocolytic agent: A new proposal of a therapeutic approach;O atosibano como agente tocolítico: Uma nova proposta de esquema terapêutico

Revista Brasileira de Ginecologia e Obstetricia

Volumn 30, Issue 2, 2008, Pages 87-92

  Cabar, Fábio Roberto ^a,b   Bittar, Roberto Eduardo ^a   Gomes, Cláudia Messias ^a   Zugaib, Marcelo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Obstetric labor, premature drug therapy; Oxytocin antagonists inhibitors; Terbutaline; Tocolysis methods; Tocolytic agents adverse effects

Indexed keywords

ARGIPRESTOCIN; ATOSIBAN; DRUG DERIVATIVE; UTERUS SPASMOLYTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; PREGNANCY; PROSPECTIVE STUDY;

ADULT; FEMALE; HUMANS; PREGNANCY; PROSPECTIVE STUDIES; TOCOLYTIC AGENTS; VASOTOCIN;

EID: 45749098204     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0100-72032008000200007     Document Type: Article

References (21)

1. Zugaib M. Prematuridade. In: Zugaib M, editor. Obstetrícia. Barueri: Manole; 2008. p. 645-66.
2. Coll RP, Albadejo MC, Bardón RF, Checa MJ. Análisis de la problemática del parto prematuro. Una visión epidemioló gica. In: Roura LC, editor. Parto prematuro. Madrid: Medica Panamericana; 2004. p. 1-10.
3. March of Dimes Perinatal Data Centers. PeriStats [ Internet]. 2008 [cited 2008 Feb 12]. Available from: http://www.marchofdimes.com/peristats/tlanding. aspx?reg=99&lev=0&to p=3&slev=1&dv=qf
4. Bittar RE. Trabalho de parto prematuro. In: Zugaib M, Bittar RE, editores. Protocolos assistenciais da clínica obstétrica da FMUSP. 3a ed. São Paulo: Atheneu; 2007. p. 537-44.
5. Perroni AG, Bittar RE, Fonseca ESB, Messina ML, Marra KC, Zugaib M. Prematuridade eletiva: aspectos obstétricos e perinatais. Rev Ginecol Obstet. 1999;10(2):67-71.
6. Souza E, Santos JFK, Bancher MM, Bertini AM, Camano L. Considerações sobre a prematuridade eletiva na Universidade Federal de São Paulo. Rev Bras Ginecol Obstet. 1995;17(6):583-9.
7. ACOG Committee Opinion. Antenatal corticosteroid therapy for fetal maturation. Number 147-December 1994. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1995;48(3):340-2.
8. Goodwin TM, Paul R, Silver H, Spellacy W, Parsons M, Chez R, et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am J Obstet Gynecol. 1994;170(2):474-8.
9. Moutquin JM, Sherman D, Cohen H, Mohide PT, Hochner-Celnikier D, Fejgin M, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol. 2000;182(5):1191-9.
10. Husslein P, Cabero Roura L, Dudenhausen JW, Helmer H, Frydman R, Rizzo N, et al. Atosiban versus usual care for the management of preterm labor. J Perinat Med. 2007;35(4):305-13.
11. Grignaffini A, Soncini E, Ronzoni E, Lo Cane F, Anfuso S, Nardelli GB. Clinical practice evaluation of combination of atosiban, ritodrine and ketoprofen for inhibiting preterm labor. Minerva Ginecol. 2007;59(5):481-9.
12. Shim JY, Park YW, Yoon BH, Cho YK, Yang JH, Lee Y, et al. Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. BJOG. 2006;113(11):1228-34.
13. Tan TC, Devendra K, Tan LK, Tan HK. Tocolytic treatment for the management of preterm labour: a systematic review. Singapore Med J. 2006;47(5):361-6.
14. Phaneuf S, Asbóth G, MacKenzie IZ, Melin P, López Bernal A. Effect of oxytocin antagonists on the activation of human myometrium in vitro: atosiban prevents oxytocin-induced desensitization. Am J Obstet Gynecol. 1994;171(6):1627-34.
15. Goodwin TM, Valenzuela G, Silver H, Hayashi R, Creasy GW, Lane R. Treatment of preterm labor with the oxytocin antagonist atosiban. Am J Perinatol. 1996;13(3):143-6.
16. European Atosiban Study Group. The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study. Acta Obstet Gynecol Scand. 2001;80(5):413-22.
17. Worldwide Atosiban versus Beta-agonist Study Group. Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labor. Br J Obstet Gynaecol. 2001;108(2):133-42.
18. Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev. 2005;(3):CD004452.
19. Romero R, Sibai BM, Sanchez-Ramos L, Valenzuela GJ, Veille JC, Tabor B, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol. 2000;182(5):1173-83.
20. da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188(2):419-24.
21. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH; Fetal Medicine Foundation Second Trimester Screening Group. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007;357(5):462-9.